Nasdaq:US$9.56 (+0.50) | HKEX:HK$15.34 (+0.18) | AIM:£1.50 (+0.01)
2000
FOUNDED
HCM
NASDAQ &
LONDON AIM
13
HKEX
12
IN-HOUSE DISCOVERED
CLINICAL STAGE DRUG CANDIDATES
3
APPROVED & MARKETED
PRODUCTS IN CHINA
1
NDA SUBMITTED IN THE US &
MAA SUBMITTED TO THE EMA
~40
CLINICAL TRIALS
AROUND THE GLOBE
4,600
PERSONNEL ACROSS
THE GROUP

OUR SCIENCE

Our core research and development philosophy is to take a holistic approach and treat cancer and immunological diseases through multiple modalities and mechanisms. We have taken a science-focused approach to develop highly selective, potent and well-tolerated cancer therapies that are deliberately engineered to improve drug exposure and reduce off-target toxicities.

R&D Philosophy Pipeline Products

Events, Circulars And Forms


Corporate Presentation for Investors 2022-05-20
Deutsche Bank ADR Virtual Investor Conference (dbVIC) 2022-05-11
CICC Healthcare Forum 2022-05-10